Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 601–700 of 860
Hsieh, C. C., Lo, Y., Li, S., Lin, T., Chang, C., Chen, T., Yang, S., Lee, Y., & Chen, Y. (2020) · Brain Pathology · doi:10.1111/bpa.12870 · Cited by 12
“Previous reports have indicated that this mouse model shows cognitive deficits without the presence of seizures and brain malformations such as cortical tubers, subependymal nodules and subependymal giant cell astrocytomas (36, 76).”
BackgroundMethodResultInfluentialTuberous sclerosis complex: everything old is new again
Ess, K. C. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9014-y · Cited by 10
“abnormalities are mTORC1-dependent by response to rapamycin [45].”
BackgroundTuberous sclerosis complex: genetic basis and management strategies
Crino, P. B., & Tsai (2012) · Advances in Genomics and Genetics · doi:10.2147/agg.s19837 · Cited by 12
“109–111 Tsc2 + / - mice have also been shown to have aberrant retino-geniculate projections with EphA receptor-dependent axon guidance in the visual system.”
Greene-Colozzi, E. A., Sadowski, A. R., Chadwick, E., Tsai, P. T., & Şahin, M. (2014) · Epilepsy Research and Treatment · doi:10.1155/2014/784137 · Cited by 10
Perspectives on the Role of Endocannabinoids in Autism Spectrum Disorders
Yeh, M. L., & Levine, E. S. (2017) · OBM Neurobiology · doi:10.21926/obm.neurobiol.1702005 · Cited by 11
“Additionally, there are several converging lines of evidence that indicate mGluR signaling is downstream of mTOR signaling in regulating long-term potentiation (LTP) [12,13] and long-term depression (LTD) [10,11].”
BackgroundThe Route to ‘Chemobrain’ - Computational probing of neuronal LTP pathway
Fahim, A., Rehman, Z., Bhatti, M. F., Virk, N., Ali, A., Rashid, A., & Paracha, R. Z. (2019) · Scientific Reports · doi:10.1038/s41598-019-45883-9 · Cited by 10
Reversal of memory and autism-related phenotypes in Tsc2+/− mice via inhibition of Nlgn1
Chalkiadaki, K., Statoulla, E., Zafeiri, M., Haji, N., Lacaille, J., Powell, C. M., Jafarnejad, S. M., Khoutorsky, A., & Gkogkas, C. G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1205112 · Cited by 9
“, 2011), deficits in learning and memory (Ehninger et al., 2008) and autism-related behaviors such as changes in social interaction (Sato et al.”
BackgroundResultHsieh, C. C., Lo, Y., Wang, H., Shen, H.-Y., Chen, Y., & Lee, Y. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02752-y · Cited by 9
“Previous reports have indicated that this mouse model shows cognitive de fi cits and autistic-like behavior without the presence of seizures and brain malformations such as cortical tubers, subependymal nodules, and subependymal giant cell astrocytoma [40, 41].”
ResultMolecular Genetics of Intellectual Disability
Bessa, C., Lopes, F., & Maciel, P. (2012) · InTech eBooks · doi:10.5772/31269 · Cited by 10
“With regard to learning abnormalities, rapamycin was able to normalize impaired LTP and spatial learning in the Tsc2+/- heterozygous knockout mice (Ehninger et al., 2008).”
BackgroundTargeted therapy for tuberous sclerosis complex
Белоусова, Е. Д., Владимирович, В. Д., Pivovarova, A. M., Katysheva, O., & Dorofeeva, M. Y. (2016) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2016-61-5-106-112 · Cited by 10
Fine-tuning of mTOR signaling by the UBE4B-KLHL22 E3 ubiquitin ligase cascade in brain development
Kong, X., Shu, X., Wang, J., Liu, D., Ni, Y., Zhao, W., Wang, L., Gao, Z., Chen, J., Yang, B., et al. (2022) · Development · doi:10.1242/dev.201286 · Cited by 9
Establishment of Tsc2-deficient rat embryonic stem cells
ITO, Y., Kawano, H., Kanai, F., Nakamura, E., Tada, N., Takai, S., Horie, S., Arai, H., Kobayashi, T., & Hino, O. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2913 · Cited by 8
Subependymal Giant Cell Astrocytomas
Franz, D. N., Krueger, D. A., & Balko, M. G. (2010) · Wiley eBooks · doi:10.1002/9783527630073.ch11 · Cited by 8
Specchio, N., Micco, V. D., Scheper, M., Aronica, E., & Curatolo, P. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105740 · Cited by 9
“40,86,87 Th early use of mTORC1 inhibitors may improve white matter abnormalities.”
Saxena, A., & Sampson, J. R. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.09.018 · Cited by 8
Sugiura, H., Shimada, T., Moriya‐Ito, K., Goto, J.-I., Fujiwara, H., Ishii, R., Shitara, H., Taya, C., Fujii, S., Kobayashi, T., et al. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0449-21.2022 · Cited by 7
Caveat mTOR: aberrant signaling disrupts corticogenesis
Osborne, L. R. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43030 · Cited by 7
Shorvon, S. D., Andermann, F., & Guerrini, R. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511921001.016 · Cited by 7
Davies, D. M., & Sampson, J. R. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.064113 · Cited by 7
“which may reflect an interplay between the effects of seizures, developmental structural abnormalities of the brain, mass lesions and abnormal neuronal function.”
BackgroundGene Therapy for Rett Syndrome: Prospects and Challenges
Gadalla, K. K. E., Ross, P. D., Hector, R. D., Bahey, N. G., Bailey, M. E. S., & Cobb, S. (2015) · Future Neurology · doi:10.2217/fnl.15.29 · Cited by 9
Autophagy in Neurodevelopmental Disorders
Lv, M., & Ma, Q. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4272-5_11 · Cited by 7
Zhang, X., Xue, H., Zhu, C., Ji, C., Li, Y. M., & Liu, W. T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1829127 · Cited by 8
Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders
Srivastava, S., Şahin, M., & Prock, L. A. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00022-9 · Cited by 9
Tsc1 Haploinsufficiency Leads to Pax2 Dysregulation in the Developing Murine Cerebellum
Serra, I., Stravs, A., Osório, C., Oyaga, M. R., Schonewille, M., Tudorache, C., & Badura, A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.831687 · Cited by 6
Down syndrome DSCR1 causes spine pathology via the Fragile X‐related protein FMRP
Roselli, F. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.239 · Cited by 6
“Furthermore, inhibition of overactive mTOR by rapamycin also improves electrophysiological and behavioural readouts in Tcs2 mice (Ehninger et al, 2008).”
BackgroundMammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
Kim, W. S. (2011) · Korean Journal of Pediatrics · doi:10.3345/kjp.2011.54.6.241 · Cited by 7
RetractedmTOR Involvement in the Mechanisms of Memory
Giovannini, M. G., & Lana, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00018-9 · Cited by 8
Can we change the course of epilepsy in tuberous sclerosis complex?
Curatolo, P., & Moavero, R. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02528.x · Cited by 6
“Rapamycin suppresses neuronal hypertrophy and recently proved its efficacy in preventing epilepsy in mouse models (Ehninger et al., 2008; Zeng et al., 2008) and in reducing seizure frequency in a patient with drug-resistant TSC (Muncy et al., 2009).”
BackgroundAliashrafzadeh, H., Liu, D., Alba, S. D., Akbar, I., Lui, A., Vanleuven, J., Martin, R. M., Wang, Z., & Liu, D. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008116 · Cited by 7
Applying biologically anchored subtypes to advance precision medicine in autism spectrum disorder
Choi, T.-Y., Gunawan, A., Seo, D., Park, J., Ahn, E. H., Suh, S. W., Fuccillo, M. V., & Choi, K. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107219 · Cited by 5
Bonniaud, B., Luu, M., Cormier, C., Racine, C., Espitalier, A., Malbranche, C., Rega, A., Gaumet, T., Kuentz, P., Vabres, P., et al. (2025) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2025.105012 · Cited by 5
Li, F., Chen, Y., Zheng, W., Li, K., & Zhou, C. Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177974 · Cited by 6
Hu, L., Shi, X., Yang, X., Liu, M., & Zou, L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001131 · Cited by 5
López‐Aranda, M. F., Boxx, G. M., Phan, M., Bach, K., Mandanas, R., Herrera, I., Taloma, S. E., Thadani, C., Lu, O., Bui, R., et al. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.03.015 · Cited by 5
“In addition, other forms of hippocampal-dependent memory, including contextual fear memory (7,9,11,12), are impaired in TSC mouse models.”
BackgroundMethodInfluentialSelf-citationSpine morphogenesis and synapse formation in tubular sclerosis complex models
Shimada, T., & Yamagata, K. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1019343 · Cited by 8
“In Tsc2 mice, spine dysmorphogenesis and synapse abnormalities were observed, and the mice showed cognitive deficits (Ehninger et al., 2008; Sugiura et al., 2015).”
BackgroundResultInfluentialAutism Spectrum Disorders in Tuberous Sclerosis
Jülich, K., & Şahin, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4788-7_184 · Cited by 5
Anchisi, L. (2012) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000136 · Cited by 5
“CI-1011, a [(2,4,6-tris(1-methylethyl)phenyl) acetyl]sulfamic acid, 2,6-bis(1methylethyl)phenyl ester, also known as avasimibe, is suitable for clinical use because of an improved pharmacological and safety profile, however, little is known about its BBB penetrability [15].”
BackgroundInfluentialReversing Disorders of Neuronal Migration and Differentiation in Animal Models
Manent, J., & LoTurco, J. J. (2012) · Oxford University Press eBooks · doi:10.1093/med/9780199746545.003.0088 · Cited by 6
Al-Futaisi, A. M., Idris, A. B., Alsayegh, A., & Al‐Mamari, W. (2016) · Sultan Qaboos University medical journal · doi:10.18295/squmj.2016.16.04.022 · Cited by 5
Roberts, T. P. L., Gandal, M. J., Siegel, S. J., Rodrigues, P. V., & Welsh, J. P. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.017 · Cited by 5
Waltereit, R., Feucht, M., de Vries, M. C., Huemer, J., Roessner, V., & de Vries, P. J. (2018) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917/a000604 · Cited by 7
Rajagopal, L., Huang, M., He, W., Ryan, C., Elzokaky, A., Banerjee, P., & Meltzer, H. Y. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4042881 · Cited by 5
Jeong, S. Y. (2025) · Cureus · doi:10.7759/cureus.96018 · Cited by 13
“In fact, in TSC2-deficient mice, overactive mTOR leads to a learning deficit rather than a benefit, likely due to improper storage of unprocessed information [124,125].”
Genetics of X-Linked Intellectual Disability
Schwartz, C. E., & Boccuto, L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800109-7.00003-0 · Cited by 6
mTOR in Acquired and Genetic Models of Epilepsy
Wong, M., Bordey, A., & Danzer, S. C. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780197549469.003.0004 · Cited by 9
Yang, Z., Teaney, N. A., Buttermore, E. D., Şahin, M., & Saber, W. A. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1524577 · Cited by 6
A Candidate Circuit Approach to Investigating Autism
Page, D. T. (2011) · The Anatomical Record · doi:10.1002/ar.21473 · Cited by 4
Krueger, D. A., & Franz, D. N. (2011) · Future Neurology · doi:10.2217/fnl.10.82 · Cited by 5
Tuber-Less Models of Tuberous Sclerosis Still Provide Insights into Epilepsy
Wong, M. (2015) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7597-15.3.129 · Cited by 4
Swiech, L. J., Urbańska, M., Macias, M., Skalecka, A., & Jaworski, J. (2012) · Neuromethods · doi:10.1007/978-1-61779-824-5_17 · Cited by 4
Zebrafish Model of Cognitive Dysfunction
Choo, B. K. M., & Shaikh, M. F. (2018) · InTech eBooks · doi:10.5772/intechopen.74456 · Cited by 5
Xiong, L.-L., Dong, X., Xue, L., Chen, J.-J., Al‐Hawwas, M., Zhu, Z.-Q., & Wang, T.-H. (2022) · Ibrain · doi:10.1002/ibra.12051 · Cited by 5
Gianessi, L., Magini, A., Dominici, R., Giovagnoli, S., & Dolcetta, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417478 · Cited by 4
mTOR, Autophagy, Aminoacidopathies, and Human Genetic Disorders
Ainslie, G. R., Gibson, K. M., & Vogel, K. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802733-2.00010-4 · Cited by 6
Clinical and Molecular Assessment in a Female with Fragile X Syndrome and Tuberous Sclerosis
Yrigollen, C. M., Pacini, L., Nobile, V., Lozano, R., Hagerman, R. J., Bagni, C., & Tassone, F. (2016) · Journal of Genetic Disorders & Genetic Reports · doi:10.4172/2327-5790.1000139 · Cited by 5
“Additionally, mice with heterozygous loss-offunction mutations in TSC1 or TSC2 have reduced mGluR-LTD, decreased postsynaptic translation [25] and show learning and memory deficits, independently from a tumor or seizure phenotype [26].”
Ahanger, I. A., Sharma, A., & Islam, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_3 · Cited by 4
Saré, R. M., Torossian, A., Loutaev, I., & Smith, C. B. (2022) · eNeuro · doi:10.1523/eneuro.0480-21.2022 · Cited by 5
“One difference between these two models is that Tsc2Djk1/ mice are reported to have learning and memory deficits (Ehninger et al., 2008), whereas Tsc2Mjg1/ mice were not found to have learning deficits (Reith et al., 2013).”
ResultChu, C. J., & Thiele, E. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511921001.026 · Cited by 4
Translational Dysregulation in Autism
Man, H. (2014) · Cell & Developmental Biology · doi:10.4172/2168-9296.1000e124 · Cited by 5
“Both Tsc2+/- and Tsc1-/- mouse deficits are rescued by treatment with rapamycin [21].”
Serotonin Disturbance in Mouse Models of Autism Spectrum Disorders
Tamada, K., & Takumi, T. (2014) · Neuromethods · doi:10.1007/978-1-4939-2250-5_9 · Cited by 5
Drug Treatments for Core Symptoms of Autism Spectrum Disorder: Unmet Needs and Future Directions
Giovagnoli, G., Siracusano, M., Postorino, V., Curatolo, P., & Mazzone, L. (2017) · Journal of Pediatric Neurology · doi:10.1055/s-0037-1602823 · Cited by 6
Molecular mechanisms of autism as a form of synaptic dysfunction
Trifonova, E. A., Khlebodarova, T. M., & Gruntenko, N. E. (2016) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj16.217 · Cited by 7
Intellectual disabilities and genetic disorders can lead the way in translational research
de Vries, P., & Oliver, C. (2009) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2009.01209.x · Cited by 4
Alteraciones de la sinaptogénesis en el autismo. Implicaciones etiopatogénicas y terapéuticas
Peñas, J. J. G., Carral, J. D., & Pereira-Bezanilla, E. (2012) · Revista de Neurología · doi:10.33588/rn.54s01.2011708 · Cited by 7
The molecular basis of cognitive deficits in pervasive developmental disorders: Table 1.
Bhattacharya, A., & Klann, E. (2012) · Learning & Memory · doi:10.1101/lm.025007.111 · Cited by 6
Learning from the autism catastrophe: key leverage points.
Herbert, M. R. (2008) · PubMed · Cited by 5
Letters to Vavilov Journal of Genetics and Breeding
(2019) · Письма в Вавиловский журнал генетики и селекции · doi:10.18699/letters2019-5-07 · Cited by 4
Chase, J. B., Li, J., Lin, W. C., Tai, L.-H., Castro, F., Collins, A. G. E., & Wilbrecht, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.15.633099 · Cited by 5
Tabaka, O., Lawal, S. A., Triana, R. D. R., Hou, M., Fraser, A., Gallagher, A., Ruiz, K. S. A., Marmarcz, M., Dickinson, M., Oliveira, M. M., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09193-3 · Cited by 3
“While numerous studies using TSC rodent models have elucidated impairments in cognitive domains — including learningandmemory,cognitive fl exibility,andsocialrecognition 8 – 12 — there remains a signi fi cant gap in our understanding of the neurobiological substrates underlying TSC-associated anxiety.”
Distinct early development trajectories in Nf1± and Tsc2± mouse models of autism
Ferreira, H., Santos, S., Martins, J., Castelo-Branco, M. S., & Gonçalves, J. (2025) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-025-09624-6 · Cited by 3
“On the other hand, several authors observed cognitive deficits [41, 42], social impairments [43, 44], and anx-iety-related behaviors [45, 46] in the adult TSC2 animal model.”
Dual Impact of Iron Deficiency and Antibiotics on Host Metabolism: A Tissue-Level Analysis
Shoff, S., Thomas, S. P., Ji, P., Parenti, M., & Slupsky, C. M. (2025) · Metabolites · doi:10.3390/metabo15080549 · Cited by 4
Wehle, D. T., Brown, E., Stamenković, V., Kniffen, B., Harsh, F. M., & Smith, S. E. P. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70353 · Cited by 3
“In fact, haploinsufficiency of several components of the mTOR pathway is related to syndromic forms of autism (Clipperton-Allen and Page 2014; Ehninger et al. 2008), and data from mouse models and human postmortem studies (Tang et al. 2014; Nicolini et al. 2015; Zhang et al. 2016) indicate that…”
Provenzano, G., Pangrazzi, L., Poli, A., Berardi, N., & Bozzi, Y. (2015) · Journal of Visualized Experiments · doi:10.3791/52919 · Cited by 3
Inhibition of p-mTOR represses transcription of PS1 and Notch 1-signaling
Das, H. K., & Hontiveros, S. S. (2020) · Frontiers in bioscience · doi:10.2741/4851 · Cited by 3
Nasr, A., Abdel‐Sater, M. A., Hussein, N. A., Daniala, A., & Edrees, M. (2023) · Assiut University Journal of Multidisciplinary Scientific Research · doi:10.21608/aunj.2023.202022.1047 · Cited by 3
López‐Aranda, M. F., Bach, K., Bui, R., Phan, M., Lu, O., Thadani, C., Luchetti, A., Mandanas, R., Herrera, I., López-Ávalos, M. D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12010203 · Cited by 3
“Previous findings have demonstrated that the administration of rapamycin, an mTOR inhibitor, has the ability to reverse multiple phenotypes observed in Tsc2 +/ − mice [40–42].”
BackgroundSelf-citationLawson, R. J., Lipovsek, N. J., Brown, S. P., Jena, A. K., Osko, J. J., & Ransdell, J. L. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1474066 · Cited by 5
Phakomatoses and Allied Conditions
Thiele, E. A., & Korf, B. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-37101-8.00045-x · Cited by 4
Siłuszyk, A., Maryniak, A., & Jóźwiak, S. (2018) · Child Neurology · doi:10.20966/chn.2018.54.421 · Cited by 4
Turkalj, L., Mehta, M., Matteson, P. G., Prem, S., Williams, M., Connacher, R., DiCicco-Bloom, E. M., & Millonig, J. H. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-45493-7_4 · Cited by 3
Pediatric Central Nervous System Cancer Predisposition
Das, A., & Tabori, U. Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-74448-9_2 · Cited by 3
mTOR and the Regulation of Translational Capacity in Late Forms of Synaptic Plasticity
Tsokas, P., & Blitzer, R. D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1761-7_7 · Cited by 5
mTOR: Une nouvelle cible pour le traitement des troubles cognitifs de la schizophrénie ?
Marin, P., Meffre, J., & Bockaert, J. (2013) · médecine/sciences · doi:10.1051/medsci/2013291009 · Cited by 4
“Ainsi, l’administration aiguë de rapamycine restaure une plasticité synaptique normale et prévient les déficits d’apprentissage chez les souris Tsc2+/- [10].”
BackgroundPost-transcriptional Regulation by Brain-Derived Neurotrophic Factor in the Nervous System
Amen, A. M., Pham, D. L., & Meffert, M. K. (2015) · Springer eBooks · doi:10.1007/978-3-319-25124-0_14 · Cited by 5
mTOR signaling in proteostasis and its relevance to autism spectrum disorders
Faus-Garriga, J., 1 Departament de Ciències Experimentals i de la Salut, U. P. F., Novoa, I., & Ozaita, A. (2017) · AIMS Biophysics · doi:10.3934/biophy.2017.1.63 · Cited by 3
“This is the case for TS [104], PTEN-related disorders [115], FXS [116] and AS [117].”
Tuberous Sclerosis and Other mTORopathies
Jeong, A., & Wong, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00054-7 · Cited by 4
Herbert, M. R. (2009) · CRC Press eBooks · doi:10.1201/9781420068870-c18 · Cited by 6
Berg, A. T. (2010) · Springer eBooks · doi:10.1007/978-1-84882-128-6_2 · Cited by 3
Comorbidities in Epilepsies: Overview
Berg, A. T. (2010) · Springer eBooks · doi:10.1007/978-1-84882-128-6_194 · Cited by 3
From bedside to bench and back: Translating ASD models
Drozd, H. P., Karathanasis, S. F., Molosh, A. I., Lukkes, J. L., Clapp, D. W., & Shekhar, A. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.10.003 · Cited by 4
Foreword for inaugural issue of Journal of Neurodevelopmental Disorders
Insel, T. R. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9005-z · Cited by 3
“Beyond new tools, there is unprecedented excitement in the study of neurodevelopmental disorders, especially Mendelian disorders such as Fragile X syndrome, Rett syndrome, and tuberous sclerosis [2, 3, 8].”
Spence, S., & Şahin, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-91280-6_207 · Cited by 3
Overabundant endocannabinoids in neurons are detrimental to cognitive functionPreprint
Zhu, D., Zhang, J., Ma, X., Hu, M., Gao, F., Hashem, J., Lyu, J., Wei, J., Cui, Y., Qiu, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.17.613513 · Cited by 4
Trifonova, E. A., Pashchenko, A. A., Ivanov, R. A., Kochetov, A. V., & Lashin, S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010066 · Cited by 3
“As early as 2008, it was first shown that adult Tsc2+/ − mice, one of the most common syndromic autism animal models, practically overcame both behavioral deficits and learning problems after a short course of rapamycin [32].”
Xie, K., Ryan, D. P., Schröder, S., Freund, L. J., Bonn, S., Zhou, Y., & Ehninger, D. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03682-2 · Cited by 2
Self-citationAaltonen, A., Tamaki, A., Ramón, A. P., Borgkvist, A., & Santini, E. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06115-2 · Cited by 2
Genetic analysis of tuberous-sclerosis genes 1 and 2 in nonlesional focal epilepsy
Schönberger, A. R., Gembé, E., Grote, A., Witt, J., Elger, C. E., Bien, C. G., Urbach, H., Becker, A. J., & Niehusmann, P. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.03.034 · Cited by 2
Progress in The Molecular Genetic Research in Autism Spectrum Disorders
Han, X., Peng, R., Zhang, L., & Shi, Z. (2019) · Journal of Psychiatry and Psychiatric Disorders · doi:10.26502/jppd.2572-519x0068 · Cited by 2
“Inhibiting the mTOR pathway in adult Tsc2 +/mice can restore synaptic plasticity and rescue cognitive and social deficit phenotypes [55].”
BackgroundCHI, O. Z., Liu, X., Fortus, H., Werlen, G., Jacinto, E., & Weiss, H. R. (2024) · NeuroMolecular Medicine · doi:10.1007/s12017-024-08780-7 · Cited by 2
“Rapamycin has shown effectiveness in mitigating and preventing seizures and/or ASD in an animal models of TSC (Ehninger et al., 2008; Koike-Kumagai et al., 2022; Schneider et al., 2017; Tsai et al., 2012).”
BackgroundKoike-Kumagai, M., Fujimoto, M., & Wataya‐Kaneda, M. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173875 · Cited by 2
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.